Description
Trenbolone Hexahydrobenzylcarbonate (Tren Hex, Parabolan) is the medium-acting ester of Trenbolone, formed by esterification with cyclohexylmethyl carboxylic acid. The substance was approved by Negma Laboratories in France as a human medical therapeutic against cachexia under the brand name Parabolan - one of the few Trenbolone derivatives with clinical approval in human medicine.
Per study reports the elimination half-life of Tren Hex lies between Tren A (3 days) and Tren E (7-10 days), at about 5-7 days. This positions the ester as a middle-way compound: less frequent injections than Tren A, but faster cycle adjustments than Tren E. In recreational research practice Tren Hex is injected twice per week.
Pharmacology is identical to all Tren esters: high androgen receptor affinity, no aromatization, progestagenic residual action. The typical Tren effects (night sweats, aggression, sleep disturbances, lipid profile worsening, prolactin elevation) are present under Tren Hex.
The original Parabolan formulation was withdrawn from the French market in 1997. In the international recreational community Tren Hex remains established as a standard medium ester, often produced by underground laboratories.
Trenbolone is on the WADA banned list.
You can order Trenbolone Hexahydrobenzylcarbonate as an oily injection solution in 10-pack at 100mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Trenbolone Hexahydrobenzylcarbonate shares the full risk profile of all Tren esters - the medium half-life only changes the injection frequency, not the documented physiological effects.
Documented in studies and the application literature:
- Progestagenic and prolactinergic action: Trenbolone acts progestagenically and drives prolactin levels up. Prolactin-mediated effects are documented. Trenbolone does not aromatize.
- Suppression of endogenous production: Trenbolone strongly suppresses endogenous testosterone production. Testicular atrophy and reduced fertility are documented, a separate test base is mandatory in research practice.
- Tren-typical effects: user reports describe night sweats, sleep disturbances and aggression.
- Cardiovascular and liver: the literature describes an unfavorable lipid profile, cardiac effects are documented in preclinical models. Hepatotoxicity is lower than under oral 17-alpha-methyl steroids but not negligible.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - American Journal of Physiology-Endocrinology and Metabolism 2011, Yarrow et al: shows in castrated rats that the trenbolone action is tissue-selective, with pronounced muscle hypertrophy and without strong prostate stimulation and without aromatization.
- Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor - APMIS 2000, Bauer et al: measures the binding affinities of 17β-trenbolone for the androgen receptor and the progestin receptor, providing the biochemical basis for the progestagenic component of all Tren esters including Tren Hex.
- Effects of implants of trenbolone acetate, estradiol, or both, on muscle insulin-like growth factor-I, insulin-like growth factor-I receptor, estrogen receptor-α, and androgen receptor messenger ribonucleic acid levels in feedlot steers - Journal of Animal Science 2008, Pampusch et al: documents the effect of Trenbolone Acetate implants on muscle IGF-1 and AR mRNA levels - a mechanistic correlate of the muscle hypertrophy response.
- Trenbolone Improves Cardiometabolic Risk Factors and Myocardial Tolerance to Ischemia-Reperfusion in Male Rats With Testosterone-Deficient Metabolic Syndrome - Endocrinology 2016, Donner et al: preclinical study on lipid profile, body composition and cardiac ischemia-reperfusion tolerance under trenbolone treatment.
- ‘My mind pretty much went to mush’: A qualitative exploration of trenbolone in the performance and image enhancing drug community - Drug and Alcohol Review 2023, Piatkowski et al: qualitative study with user reports on sleep disturbances, aggression and cognitive effects under trenbolone.
